Results 41 to 50 of about 1,140,114 (148)
Health Technology AssessmentBackground Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through newborn screening and causes symptoms throughout the body, including the lungs and digestive system ...
Steven J Edwards +7 more
doaj +1 more source
Circulating Extracellular Vesicles: An Effective Biomarker for Cancer Progression
Frontiers in Bioscience-LandmarkExtracellular vesicles (EVs), the ubiquitous part of human biology, represent a small heterogenous, membrane-enclosed body that contains a diverse payload including genetic materials in the form of DNA, RNAs, small non-coding RNAs, etc.
Madhura Chatterjee +6 more
doaj +1 more source
, 1999 Therapeutics Letter 31 considers the importance of making unpublished clinical trial data available in the context of the approval of celecoxib. Conclusions: In this case, the only information available to help the clinician decide whether to prescribe ...
Therapeutics Initiative (University of British Columbia)
core +1 more source
Intermittent Fasting Targets Osteocyte Neuropeptide Y to Relieve Osteoarthritis
Advanced ScienceOsteoarthritis is a highly prevalent progressive joint disease that still requires an optimal therapeutic approach. Intermittent fasting is an attractive dieting strategy for improving health.
Yu‐Xuan Qian +20 more
doaj +1 more source
The role of the HIV-1 gut reservoir in driving early cardiovascular events in people living with HIV
Frontiers in Drug DiscoveryPeople with HIV (PWH), even when well-controlled on antiretroviral therapy (ART), are at an increased risk for cardiovascular disease (CVD) and CVD events including sudden cardiac death and acute myocardial infarction (MI).
Keri Kramer +14 more
doaj +1 more source
, 2001 Therapeutics Letter 39 adds new evidence to information previously published about NSAIDs in Therapeutics Letters 4 and Letter 17. It also responds to our commitment in Therapeutics Letter 31 to report on celecoxib when published trials became available.
Therapeutics Initiative (University of British Columbia)
core +1 more source
Minimising inhaled corticosteroids for COPD
African Journal of Primary Health Care & Family MedicineThis Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not ...
Benji Heran +2 more
doaj +1 more source
, 2006 Therapeutics Letter 60 presents selected summaries published by La Revue Prescrire, an independent French drug bulletin. Drugs discussed include alendronate, risedronate, topiramate, tiotropium, and neuroleptics.Medicine, Faculty ofAnesthesiology ...
Therapeutics Initiative (University of British Columbia)
core +1 more source
, 2012 Therapeutics Letter 85 presents selected direct quotes published in recent issues of Prescrire International. Topics covered include aliskiren, drugs for Alzheimer's disease, escitalopram, gabapentin, pregabalin, migraine headaches, and varenicline ...
Therapeutics Initiative (University of British Columbia)
core +1 more source
BiomedicinesParkinson’s disease (PD) is an aging-related neurodegenerative disease characterized by a progressive loss of dopamine (DA)-secreting neurons in the substantia nigra. Most of the currently available treatments attempt to alleviate the disease symptoms by
David J. Rademacher +2 more
doaj +1 more source